ABSI Key Statistics, Chart & Performance
The current stock price of ABSI is 3.44 USD. In the past month the price decreased by -2.27%. In the past year, price increased by 20.49%.
ABSI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.53 | 392.98B | ||
| AMGN | AMGEN INC | 15.04 | 177.08B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.30B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.94 | 118.67B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.78 | 84.09B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 787.2 | 53.04B | ||
| INSM | INSMED INC | N/A | 37.19B | ||
| NTRA | NATERA INC | N/A | 32.19B | ||
| BIIB | BIOGEN INC | 11.26 | 27.64B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.43 | 20.95B | ||
| INCY | INCYTE CORP | 16.62 | 20.95B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 21.65B |
Related stock screener links
About ABSI
Company Profile
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Company Info
ABSCI CORP
18105 Se Mill Plain Blvd
Vancouver Washington WASHINGTON US
CEO: Sean McClain
Employees: 156
Phone: 13609491041
ABSCI CORP / ABSI FAQ
What does ABSCI CORP do?
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Can you provide the latest stock price for ABSCI CORP?
The current stock price of ABSI is 3.44 USD.
Does ABSCI CORP pay dividends?
ABSI does not pay a dividend.
What is the ChartMill technical and fundamental rating of ABSI stock?
ABSI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for ABSCI CORP?
ABSCI CORP (ABSI) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for ABSCI CORP?
The Revenue of ABSCI CORP (ABSI) is expected to decline by -18.65% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ABSI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ABSI. When comparing the yearly performance of all stocks, ABSI turns out to be only a medium performer in the overall market: it outperformed 55.39% of all stocks.
ABSI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABSI. The financial health of ABSI is average, but there are quite some concerns on its profitability.
ABSI Financial Highlights
Over the last trailing twelve months ABSI reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 3.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.78% | ||
| ROE | -54.49% | ||
| Debt/Equity | 0 |
ABSI Forecast & Estimates
15 analysts have analysed ABSI and the average price target is 8.42 USD. This implies a price increase of 144.83% is expected in the next year compared to the current price of 3.44.
For the next year, analysts expect an EPS growth of 8.18% and a revenue growth -18.65% for ABSI